

Website Supplemental Information

Page 1- Supplemental Information: Deal Related Amortization

Page 2 - Supplemental Information: FY17 Constant Currency Growth Rates

Page 3 - Historical revenue by Product Category

Deal Related Amortization

Supplemental Information - Deal Related Amortization

(\$ Millions, except per Share Data)

	FY15	Q116	Q216	Q316	Q416	FY16	Q117	FY17 Guidance
Adjusted Net Income	\$ 75	\$ 13	\$ 17	\$ 19	\$ 14	\$ 63	\$ 8	\$53-\$58
Deal Amortization	\$ 30	\$ 7	\$ 7	\$ 7	\$ 7	\$ 29	\$ 7	\$ 27
Tax Effect of Deal Amortization	\$ (9)	\$ (2)	\$ (2)	\$ (2)	\$ (2)	\$ (8)	\$ (2)	\$ (7)
Adjusted Net Income - Before Deal Amortization	\$ 96	\$ 18	\$ 23	\$ 25	\$ 19	\$ 84	\$ 13	\$73-\$78
Adjusted Earnings Per Share	\$ 1.45	\$ 0.24	\$ 0.34	\$ 0.38	\$ 0.27	\$ 1.23	\$ 0.15	\$1.01- \$1.11
Deal Amortization, EPS	\$ 0.40	\$ 0.10	\$ 0.10	\$ 0.10	\$ 0.09	\$ 0.40	\$ 0.10	\$0.39
Adjusted Earnings Per Share - Before Deal Amortization	\$ 1.85	\$ 0.35	\$ 0.44	\$ 0.48	\$ 0.36	\$ 1.63	\$ 0.25	\$1.40- \$1.50

FY17 Product Category Growth Rates in Reported a

	Q1 % Growth - Constant Currency	Q1 % Growth - Reported Currency
Plasma	12.3%	10.3%
Hemostasis	11.5%	9.3%
Cell Processing	-2.9%	-6.2%
Donor	-13.3%	-14.6%
Total Revenue	0.3%	-1.6%

Historical Product Category Growth Rates in Reported Currency

(\$ Millions)

	<u>Q116</u>	<u>Q216</u>	<u>Q316</u>	<u>Q416</u>	<u>FY16</u>	<u>Q117</u>
Total Revenue	\$ 213	\$ 220	\$ 233	\$ 242	\$ 909	\$ 210
<i>By Product Category:</i>						
Plasma	\$ 89	\$ 93	\$ 101	\$ 100	\$ 382	\$ 98
Hemostasis	\$ 14	\$ 14	\$ 15	\$ 17	\$ 59	\$ 15
Cell Processing	\$ 28	\$ 28	\$ 28	\$ 29	\$ 112	\$ 26
Blood Center	\$ 83	\$ 84	\$ 90	\$ 97	\$ 356	\$ 71